RxDoctor Payments Data

Peter Ankoh, MD

Internal Medicine · Leesburg, FLNPI 1720044241

Payments from drug & device makers

$662in general payments, 2019–2025

Across 29 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$134
  • Amgen$96
  • Astellas Pharma US Inc$95
  • GSK$63
  • Mannkind Corporation$59
  • Amarin Pharma, Inc.$53
  • plus $161 from 7 others

What the payments were for

  • Food & beverage$52780%
  • Education$7511%
  • Gifts$599%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$662 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$278,344
Medicare patients
503
Services billed
2,553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban244$269,393
OzempicSemaglutide144$200,556
MounjaroTirzepatide126$176,576
JardianceEmpagliflozin84$83,455
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$60,460
JanuviaSitagliptin Phosphate48$59,514
EntrestoSacubitril/Valsartan28$37,552
LinzessLinaclotide52$36,110
FarxigaDapagliflozin Propanediol38$35,104
MyrbetriqMirabegron37$25,845
Repatha SureclickEvolocumab18$18,087
ZenpepLipase/Protease/Amylase11$16,597
VascepaIcosapent Ethyl22$16,362
XareltoRivaroxaban15$15,392
TrulicityDulaglutide13$14,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$134$269,393244 claims
Novo NordiskOzempic$19$200,556144 claims
GSKTrelegy Ellipta$63$60,46053 claims
AstraZenecaFarxiga, Brilinta, Symbicort$33$50,10570 claims
NovartisEntresto$45$37,55228 claims
Astellas Pharma US IncMyrbetriq$95$25,84537 claims
Johnson & JohnsonXarelto$14$15,39215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Leesburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →